Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis

Horizon Therapeutics logo

Horizon Therapeutics

Status and phase

Completed
Phase 2
Phase 1

Conditions

Cystinosis

Treatments

Drug: RP103
Drug: Cystagon®

Study type

Interventional

Funder types

Industry

Identifiers

NCT00872729
RP103-01

Details and patient eligibility

About

Cystinosis is an inheritable disease that if untreated, results in kidney failure as early as the first decade of life. The current marketed therapy is Cystagon® (cysteamine bitartrate) which must be taken every six hours for the rest of the patient's life to prevent complications of cystinosis. RP103 is a formulation of cysteamine bitartrate that is being studied to see if it may be able to be given less frequently, once every 12 hours, and have similar results.

Full description

This is a single-dose, open-labeled, non-randomized, two-period study of Cysteamine Bitartrate Delayed-release Capsules (RP103) and Cystagon® in up to 10 patients (male or female) with nephropathic cystinosis under fasting conditions. It will involve a 4 night check-in to a clinical research center.

Enrollment

9 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male and female subjects must have nephropathic cystinosis.
  • Children less than 22.5 kg will only be included in the study if the investigator feels they can safely participate in the study including the required blood draw volume for the safety and PK/PD assessments.
  • Subjects must be on a stable dose of Cystagon® at least 21 days prior to Screening.
  • Subjects must be able to swallow a 150 mg Cystagon® capsule with the capsule intact.
  • Within the last 2 months, no clinically significant change in liver function [i.e., ALT, AST, alkaline phosphatase, bilirubin (total and direct)] and renal function [i.e., serum creatinine, albumin, total protein] at Screening as determined by the Investigator.
  • Sexually active female subjects of childbearing potential (i.e., not surgically sterile [tubal ligation, hysterectomy, or bilateral oophorectomy] or at least 2 years naturally postmenopausal) must agree to utilize the same acceptable form of contraception from screening through completion of the study.
  • Subjects or their authorized caregiver must provide written informed consent and assent (where applicable) prior to participation in the study.
  • If in the opinion of the investigator, patients can safely provide the study required blood draw volume.
  • Subjects must be willing and able to comply with the study restrictions and requirements.

Exclusion criteria

  • If, in the opinion of the investigator, the planned study dose would exceed the patient's tolerability of cysteamine based on their prior Cystagon® steady state drug requirements.
  • Evidence of or verbal attestation of Helicobacter pylori infection, presently, or within the last 90 days prior to Screening.
  • Subjects with a known history, currently or within the past 90 days prior to Screening, of the following conditions or other health issues that make it, in the opinion of the investigator, unsafe for them to participate, or whose concomitant medical problems preclude them from committing to the study schedule including the following: Crohn's disease, inflammatory bowel disease (if currently active) or have had prior resection of small intestine; • History of heart disease, e.g., myocardial infarction, heart failure, arrhythmias; Any bleeding disorder; Malignant disease; Severe liver disease as defined as ALT or AST > 2 times the upper limit of normal.
  • Subjects who have had a kidney transplant.
  • Subjects who are planning or are a registered candidate for a kidney transplant within 3 months of the Screening or have a serum creatinine > 2.4.
  • Subjects with known hypersensitivity to cysteamine.
  • If female (of child-bearing potential), are nursing, planning a pregnancy, known or suspected to be pregnant, or have a positive urine pregnancy screen.
  • Patients with a hemoglobin level < 10.5.
  • Subjects who have a made a blood donation within 60 days prior to study initiation.
  • Subjects who, in the opinion of the Investigator, are not able or willing to comply with the protocol.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

9 participants in 2 patient groups

Cystagon®
Active Comparator group
Description:
Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg
Treatment:
Drug: Cystagon®
RP103
Experimental group
Description:
Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg
Treatment:
Drug: RP103

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems